Court Opinion

ID: 3189312
Source: CourtListenerOpinion
Date Created: 2016-03-28 22:05:47.26874+00
Date Added: 2024-06-11T13:25:46.822793
License: Public Domain

1       IN THE COURT OF APPEALS OF THE STATE OF NEW MEXICO

 2 Opinion Number:

 3 Filing Date: March 28, 2016

 4 NO. 33,127

 5 ALBERT RODARTE,

 6        Appellant-Respondent,

 7 v.

 8 PRESBYTERIAN INSURANCE COMPANY,

 9        Appellee-Petitioner,

10 and

11 NEW MEXICO SUPERINTENDENT
12 OF INSURANCE,

13        Appellee.

14 APPEAL FROM THE DISTRICT COURT OF SANTA FE COUNTY
15 Raymond Z. Ortiz, District Judge

16 Paul D. Mannick
17 Santa Fe, NM

18 for Appellant-Respondent
1   Montgomery & Andrews, P.A.
2   Walter J. Melendres
3   Seth C. McMillan
4   Santa Fe, NM

5 for Appellee-Petitioner
 1                                        OPINION

 2 HANISEE, Judge.

 3   {1}   This case requires us to determine whether certain medical treatment is covered

 4 by a plan participant’s health benefits plan or required by applicable regulations

 5 governing such contracts. After Albert Rodarte’s (Rodarte) daughter, Jessica, suffered

 6 a severely disabling anoxic brain injury, he sought pre-approval from her health

 7 insurance company for Jessica to receive hyperbaric oxygen therapy (HBOT).

 8 Presbyterian Insurance Company (Presbyterian) denied the request, concluding that

 9 the treatment was not a covered benefit. On review, the New Mexico Superintendent

10 of Insurance (the Superintendent) upheld Presbyterian’s denial of coverage, finding

11 that HBOT was an excluded treatment under her Presbyterian plan, and that the use

12 of HBOT to treat Jessica’s condition was not “medically necessary” under the New

13 Mexico Administrative Code (the Code).1 In its appellate capacity, the district court

14 disagreed and reversed the Superintendent in both respects.

15   {2}   On petition by Presbyterian, this Court accepted certiorari in order to review the

           1
17          Grievance Procedures within the Code were revised effective January 1, 2016.
18   Many regulations, including some pertinent to this appeal, have been renumbered and
19   in some instances modified. In this Opinion, we cite to and apply the regulations in
20   place during the course of the underlying proceedings. We note differences to
21   applicable regulations when necessary or helpful to an understanding of our analysis.
 1 district court’s ruling. We hold that Jessica’s condition was excluded from those for

 2 which her Presbyterian health benefits plan provided HBOT coverage. We also hold

 3 that HBOT was not a medically necessary treatment for Jessica’s condition under the

 4 Code. We therefore reverse the district court.

 5 BACKGROUND

 6   {3}   Jessica’s injury, identified as “global anoxic encephalopathy,” resulted from an

 7 incident of cardiac arrest and stroke that deprived her brain of oxygen for

 8 approximately seventeen minutes. At the time, Jessica was a freshman at New Mexico

 9 State University. Her injury left her profoundly impaired both mentally and physically.

10 After researching Jessica’s condition on the internet and learning of HBOT, Rodarte

11 contacted Dr. Kenneth Stoller, who owned and operated a facility offering the

12 treatment. When treated by HBOT, a patient is “enclosed in a pressure vessel and

13 exposed to 100% oxygen at increased atmospheric pressure.” While acknowledging

14 that HBOT is “off-label,” Dr. Stoller nonetheless maintained it to be a “well-

15 established FDA approved treatment used for a wide variety of conditions[.]” He

16 requested prior authorization from Presbyterian to treat Jessica with a series of forty

17 HBOT sessions.

18   {4}   Presbyterian denied Dr. Stoller’s request because Jessica did “not meet the

19 requirements for the requested” HBOT under the terms of her insurance contract, and

                                               2
 1 because her diagnosis was “a specifically excluded condition for [HBOT] per

 2 Presbyterian . . . criteria.” When Rodarte requested “adverse determination review”

 3 through Presbyterian’s internal process of appeal,2 Presbyterian twice upheld its denial

 4 of coverage. It first explained that “HBOT is not a covered benefit . . . due to

 5 [Jessica’s] cerebral vascular injury[,]” and later elaborated that its decision was

 6 additionally justified by the absence of “evidence in the literature that supports

 7 treatment with HBOT for Jessica’s condition.” Presbyterian added that “experimental

 8 or investigational services [or] treatments are not covered benefits.”

 9   {5}   As permitted by the Code,3 Rodarte then sought external review by the

10 Superintendent. After first determining that Rodarte’s grievance qualified for external

11 review of an experimental or investigational treatment under 13.10.17.28 NMAC

12 (5/15/2012), the Superintendent convened a hearing panel to issue a recommendation

13 regarding the propriety of Presbyterian’s denial of coverage. The panel, comprised of

14 two physicians and one attorney, held an informal hearing at which Presbyterian and

15 Rodarte presented evidence in support of their respective positions. Utilizing the same

          2
17          See 13.10.17.17(A) NMAC (5/15/2012) (stating that “[e]very grievant who is
18 dissatisfied with an adverse determination shall have the right to request internal review
19 of the adverse determination by the health care insurer”).
         3
20         See 13.10.17.23 NMAC (5/15/2012) (setting forth process by which external
21 review by the Superintendent is initiated).

                                               3
 1 regulation initially applied by the Superintendent, the panel considered: (a) whether

 2 HBOT “reasonably appears to be a covered benefit under the plan”; (b) whether

 3 HBOT “is not explicitly listed as an exclusion under the plan”; and (c) whether HBOT

 4 is a “medical necessity.”

 5   {6}   In its ensuing written recommendation to the Superintendent, the panel noted

 6 that Rodarte sought HBOT treatment for anoxic encephalopathy, a condition for

 7 which the insurance contract did not specifically include or exclude HBOT coverage.

 8 The contract did, however, list certain conditions for which HBOT was available, and

 9 excluded “any clinical condition not listed above,” specifically naming seven such

10 excluded conditions. The panel advised, however, that “it is not practical for a [p]lan

11 to list all of the diseases and illnesses in the world that are excluded [and] . . . if anoxic

12 encephalopathy is not specifically listed as covered, then it is excluded.” The panel

13 recommended that the Superintendent uphold Presbyterian’s denial of HBOT

14 coverage under the terms of Jessica’s contract and for the additional reason that under

15 the evidence presented and considered, HBOT was not “medically necessary” as an

16 experimental or investigational treatment under the standard given in 13.10.17.28(B)

17 NMAC (5/15/2012).

18   {7}   In a final order, the Superintendent adopted, approved, and accepted the

19 findings and conclusions of the panel, adding that “even if a treatment might be

                                                 4
 1 considered a covered benefit, it must also be medically necessary before an adverse

 2 determination [of coverage] can be reversed.” Thus, the Superintendent identified the

 3 issue to be “whether as a result of [Presbyterian’s] adverse determination, [Jessica]

 4 was deprived of medically necessary covered services.” Importantly, the

 5 Superintendent did not disturb the panel’s conclusion that because “anoxic

 6 encephalopathy is not specifically listed as covered, then it is excluded” from coverage

 7 under Presbyterian’s plan. The Superintendent then made a specific finding that “[t]he

 8 HBOT treatment denied by Presbyterian in this case does not meet the requirements

 9 necessary to establish medical necessity pursuant to 13.10.17(B) NMAC

10 [(5/15/2012)].”4 By the Superintendent’s order, Presbyterian’s adverse determination

11 was upheld.

12   {8}   Having failed to convince Presbyterian or the Superintendent that HBOT was

13 a covered benefit for Jessica’s condition under either her health plan contract or the

           4
13           We note that “13.10.17(B) NMAC [(5/15/2012)]” is not a provision that existed
14   or exists in the Code. It is therefore unclear which “requirements necessary to establish
15   medical necessity” were applied by the Superintendent to determine that HBOT is not
16   medically necessary to treat Jessica. As discussed in greater detail herein, the Code
17   addresses medical necessity in both 13.10.17.7(L) NMAC (5/15/2012) (defining
18   “medical necessity” in the general definitional section) and 13.10.17.28(B) NMAC
19   (5/15/2012) (setting forth the certification requirements of
20   medical necessity when requesting external review of an experimental or investigational
21   treatment adverse determination).

                                                5
 1 Code, Rodarte appealed to the district court.5 There he argued again that the insurance

 2 contract covered HBOT for Jessica’s condition, contained no effective exclusion, and

 3 was “medically necessary” under 13.10.17.28(B) NMAC (5/15/2012). Presbyterian

 4 insisted that its plan covers “medically necessary” services as defined not by the

 5 Code, but by the insurance contract itself. Presbyterian also maintained that Rodarte

 6 failed to establish that the Superintendent’s determination of non-medical necessity in

 7 this case was unsupported by substantial evidence.

 8   {9}   After initially affirming the Superintendent, the district court was persuaded by

 9 Rodarte’s motion for reconsideration that its ruling was incorrect. In granting the

10 motion to reconsider, the district court ruled that HBOT “reasonably appears to be a

11 covered benefit” under Jessica’s Presbyterian plan, and was not “explicitly listed as

12 an excluded benefit.” Applying 13.10.17.28 NMAC (5/15/2012) for the first time, the

13 district court concluded as a matter of law that “Dr. Stoller’s certification regarding

14 HBOT as a recommended treatment for Jessica [satisfied] the requirements for medical

15 necessity applicable to experimental and investigational medical procedures.” The

16 district court concluded that in its original order, it had “mistakenly applied” the “more

17 general definition of medical necessity found at 13.10.17.7[(L)] NMAC [(5/15/2012)].”

          5
22          See NMSA 1978, § 59A-4-20(A) (2011) (stating that an appeal from “an order
23 of the [S]uperintendent made after an informal . . . or . . . administrative hearing . . .
24 shall be taken to the district court”).

                                               6
1 Ultimately, the district court reversed the Superintendent. This appeal followed.

                                           7
 1 DISCUSSION

 2 Standard of Review

 3   {10}   Under NMSA 1978, Section 39-3-1.1(D) (1999), a district court may “set aside,

 4 reverse[,] or remand” the final decision of the Superintendent when: “(1) the

 5 [Superintendent] acted fraudulently, arbitrarily[,] or capriciously; (2) the final decision

 6 was not supported by substantial evidence; or (3) the [Superintendent] did not act in

 7 accordance with law.” Our review is the same as that of “the district court sitting in its

 8 appellate capacity, while at the same time determining whether the district court erred

 9 in the first appeal.” Rio Grande Chapter of Sierra Club v. N.M. Mining Comm’n,

10 2003-NMSC-005, ¶ 16, 133 N.M. 97, 61 P.3d 806.

11   {11}   We discuss: (1) whether the HBOT treatments are a covered benefit under

12 Presbyterian’s plan; (2) whether such treatments are medically necessary under

13 regulations adopted by the Superintendent requiring a plan to provide medically

14 necessary services; and (3) whether the district court was correct to reverse the

15 Superintendent.

16 I.       Presbyterian’s Insurance Contract Does Not Provide HBOT Coverage
17          for Jessica’s Medical Condition

18   {12}   The Presbyterian insurance contract states that it “helps pay for healthcare

19 expenses that are [m]edically [n]ecessary and [s]pecifically covered.” It defines

                                                8
 1 “[s]pecifically covered” to mean “only those healthcare expenses that are expressly

 2 listed and described” in the agreement. Presbyterian’s medical policy specifically

 3 covers HBOT for certain diabetic wounds, gangrene, compromised skin grafts, and

 4 a number of other conditions; however, it does not list HBOT as a covered service for

 5 global anoxic encephalopathy. Furthermore, in the “exclusions” section of the HBOT

 6 portion of the policy, the policy states, “[a]ny clinical conditions not listed above [are]

 7 not covered, including but not limited to” a list of seven conditions, including stroke.

 8   {13}   Presbyterian argues that HBOT for Jessica’s specific condition is not covered

 9 under the insurance contract as it is not an expressly covered treatment in the

10 agreement. Rodarte contends that because Presbyterian reimburses oxygen and other

11 therapeutic support care services, he “would reasonably expect that HBOT, which is

12 a method of oxygen therapy, would be among the therapeutic and support services

13 Presbyterian promised to provide.” Additionally, Rodarte maintains that because

14 HBOT falls under the plan’s coverage for short term rehabilitation services, and

15 “HBOT . . . is designed to repair and restore damaged brain tissue,” its provision

16 would be internally consistent. Rodarte claims that a contracted plan that reasonably

17 appears to cover oxygen can likewise reasonably be expected to cover HBOT for

18 global anoxic encephalopathy.

19   {14}   In construing the language of Presbyterian’s plan, we are mindful that, “absent

                                                9
 1 a statute to the contrary, insurance contracts are construed by the same principles

 2 which govern the interpretation of all contracts.” Rummel v. Lexington Ins. Co., 1997-

 3 NMSC-041, ¶ 18, 123 N.M. 752, 945 P.2d 970 (internal quotation marks and citation

 4 omitted). The process of contract interpretation “often turns upon whether . . . the

 5 contract is ambiguous.” C.R. Anthony Co. v. Loretto Mall Partners, 1991-NMSC-

 6 070, ¶ 12, 112 N.M. 504, 817 P.2d 238. “[W]hen the policy language is clear and

 7 unambiguous, [an appellate court] must give effect to the contract and enforce it as

 8 written.” Ponder v. State Farm Mut. Auto. Ins. Co., 2000-NMSC-033, ¶ 11, 129 N.M.
9 698, 12 P.3d 960. “If the court determines that the contract is reasonably and fairly

10 susceptible of different constructions, an ambiguity exists.” Mark V, Inc. v. Mellekas,

11 1993-NMSC-001, ¶ 12, 114 N.M. 778, 845 P.2d 1232. Whether an agreement contains

12 an ambiguity is a matter of law to be determined by the trial court, and is a question

13 we review de novo on appeal. Id.

14          In determining the existence of an ambiguity, the language at issue should
15          be considered not from the viewpoint of a lawyer, or a person with
16          training in the insurance field, but from the standpoint of a reasonably
17          intelligent layman, viewing the matter fairly and reasonably, in accordance
18          with the usual and natural meaning of the words, and in the light of
19          existing circumstances, prior to and contemporaneous with the making
20          of the policy.

21 Rummel, 1997-NMSC-041, ¶ 19 (internal quotation marks and citation omitted).

22   {15}   We conclude that the insurance contract unambiguously restricts coverage for

                                                10
 1 HBOT to a series of named conditions and excludes coverage of HBOT for all other

 2 treatments. Jessica’s injury does not fall within the exclusive list of covered conditions

 3 in the contract, and the contract expressly excludes all non-listed conditions from

 4 coverage. As well, the contract expressly excludes strokes, one source of Jessica’s

 5 injuries, from the scope of HBOT coverage. We are not persuaded by Rodarte’s

 6 argument that the contract’s exclusion of HBOT for all non-covered treatment is

 7 ambiguous because the contract elsewhere covers oxygen for rehabilitation treatment.

 8 Even assuming the phrase “oxygen” in the contract can be read to include HBOT, “a

 9 specific provision [in a contract] relating to a particular subject will govern in respect

10 to that subject, as against a general provision, even though the latter, standing alone,

11 would be broad enough to include the subject to which the more specific provision

12 relates.” Weldon v. Commercial Union Assurance Co., 1985-NMSC-118, ¶ 9, 103

13 N.M. 522, 710 P.2d 89 (internal quotation marks and citation omitted).

14   {16}   As did Presbyterian and the Superintendent, we therefore conclude that the

15 HBOT treatments in this case are not only not specifically covered treatments under

16 the health plan into which Presbyterian and Jessica contracted, they are specifically

17 excluded. We reverse the district court’s conclusion to the contrary.

18 II.      HBOT Is Not Medically Necessary to Treat Jessica’s Medical Condition
19          Under the Code

                                               11
 1   {17}   Our Legislature empowered the Superintendent to establish “reasonable rules

 2 and regulations necessary for or as an aid to administration or effectuation of any

 3 provision of the Insurance Code administered by the [S]uperintendent[.]” NMSA

 4 1978, § 59A-2-9(A) (1997). That authority was employed by the Superintendent to

 5 promulgate grievance procedures, which apply to “all health care insurers that provide,

 6 offer, or administer health benefit plans[.]” 13.10.17.2(A) NMAC (5/15/2012). One

 7 such regulation applicable to insurers such as Presbyterian, 13.10.13.8(C)(1) NMAC,

 8 requires, at a minimum, that evidence of health insurance coverage include “a complete

 9 statement that a covered person shall have the right . . . to available and accessible

10 services when medically necessary[.]” Therefore, even if the language in a health plan

11 specifically excludes coverage for a treatment or service, the Superintendent’s

12 regulations require that it be covered if it is medically necessary. We therefore consider

13 whether the HBOT treatments must be covered under Presbyterian’s plan because

14 they are medically necessary under the Code.

15   {18}   Regarding which treatments are medically necessary, 13.10.17.7 NMAC

16 (5/15/2012) supplies various definitions “[a]s used in this rule[.]” The meaning of

17 “medical necessity” or “medically necessary” is set forth in 13.10.17.7(L) NMAC

18 (5/15/2012). Medically necessary treatments are those

19          health care services determined by a provider, in consultation with the

                                               12
 1          health care insurer, to be appropriate or necessary, according to any
 2          applicable generally accepted principles and practices of good medical
 3          care or practice guidelines developed by the federal government, national
 4          or professional medical societies, boards and associations, or any
 5          applicable clinical protocols or practice guidelines developed by the
 6          health care insurer consistent with such federal, national, and professional
 7          practice guidelines, for the diagnosis or direct care and treatment of a
 8          physical, behavioral, or mental health condition, illness, injury, or
 9          disease[.]

10 13.10.17.7(L) NMAC (5/15/2012).6

11   {19}   That definition is either replaced, as argued by Rodarte, or remains substantively

12 applicable to the Superintendent’s grievance process, as argued by Presbyterian, when

13 the medical treatment sought under a health plan is characterized as experimental or

14 investigational. 13.10.17.28 NMAC (5/15/2012), the provision advanced by Rodarte

15 as defining medical necessity, primarily referenced by the Superintendent, and relied

16 on as the basis for the district court’s final ruling reversing the Superintendent,

17 provides:

18          If the request is for external review of an experimental or investigational
19          treatment adverse determination, insurance division staff shall also
20          consider whether:

21          A.    coverage; the recommended health care service:

22                 (1) reasonably appears to be a covered benefit under the grievant’s
23          health benefit plan except for the health care insurer’s determination that

          6
23          The definition set forth in 13.10.17.7(L) NMAC (5/15/2012) was not modified
24 under the 2016 revision to the Code. It has been renumbered as 13.10.17.7(N) NMAC.

                                                13
 1          the health care service is experimental or investigational for a particular
 2          medical condition; and

 3                (2) is not explicitly listed as an excluded benefit under the
 4          grievant’s health benefit plan; and

 5          B.    medical necessity; the grievant’s treating provider has certified
 6          that:

 7               (1) standard health care services have not been effective in
 8          improving the grievant’s condition; or

 9          (2) standard health care services are not medically appropriate for the grievant;
10 or

11                 (3) there is no standard health care service covered by the health
12          care insurer that is as beneficial or more beneficial than the health care
13          service[.]

14 13.10.17.28 NMAC (5/15/2012).7

15   {20}   Having reviewed the entire administrative record, the Superintendent specifically

16 concluded that the “HBOT treatment denied by Presbyterian does not meet the

            7
17           The 2016 revision to the Code renumbered 13.10.17.28 NMAC (5/15/2012) as
18   13.10.17.29 NMAC. Substantive changes to the language of 13.10.17.28 include the
19   substitution of “an IRO” for “insurance division staff,” and identification of the health
20   care treatment sought as both “recommended or requested.” See 13.10.17.29 NMAC.
21   As used in 13.10.17.29 NMAC, “IRO” refers to “[i]ndependent review organization,”
22   which are entities under the revised Code that can be assigned to conduct the
23   independent review. See 13.10.17.23 NMAC. Also under the 2016 revision to the
24   Code, external review of a decision by an IRO is binding upon both the grievant and
25   the health care insurer unless a grievant has and exercises a right of appeal under the
26   Patient Protection Act, NMSA 1978, § 59A-57-1 to -11 (1998, as amended through
27   2003). See 13.10.17.30(A) NMAC.

                                                14
 1 requirements necessary to establish medical necessity[,]” then cited a non-existent

 2 provision of the Code: “13.10.17(B) [NMAC (5/15/2012)].” In reversing the

 3 Superintendent, the district court relied on 13.10.17.28(B) NMAC (5/15/2012). To

 4 determine whether the district court’s reversal of the Superintendent was correct, we

 5 must determine the applicable definition in this circumstance.

 6   {21}   “[A] court’s interpretation of an administrative regulation is a question of law

 7 that we review de novo.” Truong v. Allstate Ins. Co., 2010-NMSC-009, ¶ 24, 147

 8 N.M. 583, 227 P.3d 73 (internal quotation marks and citation omitted). “In interpreting

 9 sections of the . . . Code, we apply the same rules as used in statutory interpretation.”

10 Alliance Health of Santa Teresa, Inc. v. Nat’l Presto Indus., 2007-NMCA-157, ¶ 18,

11 143 N.M. 133, 173 P.3d 55. “We look first to the plain language of the [regulation],

12 giving the words their ordinary meaning,” unless there is an indication that “a different

13 [meaning] was intended.” N.M. Indus. Energy Consumers v. N.M. Pub. Regulation

14 Comm’n, 2007-NMSC-053, ¶ 20, 142 N.M. 533, 168 P.3d 105. “When [a

15 regulation’s] language is clear and unambiguous, this Court must give effect to that

16 language and refrain from further . . . interpretation.” Marbob Energy Corp. v. N.M.

17 Oil Conservation Comm’n, 2009-NMSC-013, ¶ 9, 146 N.M. 24, 206 P.3d 135

18 (alteration, internal quotation marks, and citation omitted).

19 A. 13.10.17.28(B) NMAC (5/15/2012) Does Not Provide the Applicable

                                               15
 1          Definition of Medical Necessity Under the Code

 2   {22}   The Code details the requirements, time frames, and considerations pertinent to

 3 the filing and review of an adverse determination grievance. See 13.10.17.1 to -.40

 4 NMAC (05/03/2004, as amended through 05/15/2012). Its provisions are organized

 5 beginning with general requirements, then preliminary determinations, initial

 6 determinations, internal review, and finally external review. Id. For example, 13.10.17.6

 7 NMAC (5/15/2012) establishes “procedures for filing and processing adverse

 8 determination grievances and administrative grievances regarding actions taken or

 9 inaction by a health care insurer.” More specifically, 13.10.17.27 NMAC (5/15/2012)

10 details the “[c]riteria for initial external review of adverse determination by insurance

11 division staff[,]” setting out factors that staff must consider in deciding which

12 grievances are available for review by the Superintendent. 13.10.17.28 NMAC

13 (5/15/2012) denotes supplemental considerations in the context of external review of

14 experimental or investigational treatments, as indicated by the phrase “shall also

15 consider” in the first sentence of the provision. Regarding medical necessity, what

16 “shall also” be considered is the required certification of medical necessity by a

17 “licensed, board certified or board eligible physician qualified to practice in the area

18 of medicine appropriate to treat the grievant’s condition[.]” 13.10.17.28(B)(3)(b)

19 NMAC (5/15/2012). The language “shall also” and the fact that the section regarding

                                              16
 1 medical necessity does not supply an independent definition, but states the

 2 requirements for supplemental certification in the context of experimental or

 3 investigational treatment adverse determinations, is the first indication that

 4 13.10.17.28(B) NMAC (5/15/2012) does not replace 13.10.17.7(L) NMAC

 5 (5/15/2012)’s definition of “medical necessity.”

 6   {23}   13.10.17.29(B) NMAC (5/15/2012) next details the procedure applicable “[i]f

 7 the request for external review does not meet the criteria prescribed by 13.10.17.27

 8 [NMAC (5/15/2012)] and, if applicable, 13.10.17.28 NMAC [(5/15/2012)].” However,

 9 if the “request meets the criteria for external review,” the Superintendent notifies the

10 insurer and the grievant that an informal hearing “has been set to determine whether,

11 as a result of the health care insurer’s adverse determination, the grievant was deprived

12 of medically necessary covered services.” 13.10.17.29(C) NMAC (5/15/2012). The

13 “additional criteria” under 13.10.17.28 NMAC is plainly denoted as something that

14 “shall also” be considered upon a grievant’s request for external review involving

15 experimental or investigational treatment. Id.

16   {24}   Our review of 13.10.17.27 through -.29 NMAC (5/15/2012) suggests that the

17 criteria listed under the “medical necessity” provision of 13.10.17.28(B) NMAC

18 (5/15/2012) merely states applicable “criteria for initial external review” of the medical

19 necessity of experimental or investigational treatment, rather than supplying an

                                               17
 1 independent and superseding definition of “medical necessity” for purposes of

 2 determining whether a treatment is covered by the plan or medically necessary under

 3 the Code. See 13.10.17.29 NMAC (5/15/2012); see also State v. Ybarra, 2010-

 4 NMCA-063, ¶ 7, 148 N.M. 373, 237 P.3d 117 (“There is no difference between our

 5 review of the Administrative Code and statutes, and we determine and effectuate the

 6 intention of the administrative agency using the plain language of the regulation as the

 7 primary indicator of its intent.”). We see no indication that the “criteria for initial

 8 external review,” utilized in order to determine whether a grievant’s request for external

 9 review is to occur as “prescribed by 13.10.17.27 [NMAC (5/15/2012)] and, if

10 applicable, 13.10.17.28 [NMAC (5/15/2012)]” was also intended to substitute or

11 replace the general definition of “medical necessity” for purposes of the

12 Superintendent’s hearing. See 13.10.17.29(B) NMAC (5/15/2012); see also

13 13.10.17.29(C) NMAC (5/15/2012) (explaining role of 13.10.17.28 NMAC (5/15/2012)

14 in determining whether a request meets the criteria for external review prior to the

15 setting of an informal hearing); see also Alliance Health of Santa Teresa, Inc., 2007-

16 NMCA-157, ¶ 24 (stating that we generally do not read language into the Code).

17   {25}   In the dissenting portion of Chief Judge Vigil’s separate opinion, he reasons

18 that, in the “case of an experimental or investigational treatment, the definition of

19 ‘medical necessity’ [under 13.10.17.28(B) NMAC (5/15/2012)] governs instead of the

                                               18
 1 general definition” under 13.10.17.7(L) NMAC (5/15/2012). (Vigil, C.J., dissenting in

 2 part, and specially concurring, ¶ 40). But this perspective essentially revises the

 3 Code’s regulatory language. That the criteria for medical necessity under

 4 13.10.17.28(B) NMAC (5/15/2012) is meant to supplement, and not replace,

 5 13.10.17.7(L) NMAC (5/15/2012) is made most plain by use of the prefatory directive

 6 “shall also consider.” 13.10.17.28 NMAC (5/15/2012). Otherwise, the language would

 7 read “shall consider instead.” But it does not. We likewise consider Chief Judge

 8 Vigil’s statement that a patient can “never win when coverage is sought for an

 9 experimental or investigational treatment,” (Vigil, C.J., dissenting in part, and specially

10 concurring, ¶ 39), to be mistaken. Such a grievant must, however, establish medical

11 necessity by the same standard required of any grievant under the Code, that being the

12 general standard under 13.10.17.7(L) NMAC (5/15/12). Additionally, in order to gain

13 the opportunity for a hearing before the Superintendent, such a grievant must first

14 attain a treating provider’s separate and compliant certification of medical necessity

15 with the added strictures associated with the experimental or investigational treatment

16 sought. See 13.10.17.28(B) NMAC (5/15/12).

17   {26}   Indeed, it would make little sense that a treating provider’s contention could

18 alone establish medical necessity under the Code despite the existence of an otherwise

19 comprehensively applicable definition that both applies objective criteria and directly

                                               19
 1 incorporates a health care provider’s independent assessment of those “health care

 2 services . . . appropriate or necessary, according to generally accepted principles and

 3 practices of good medical care[.]” 13.10.17.7(L) NMAC (5/15/2012). We view

 4 13.10.17.28(B) NMAC (5/15/2012) and 13.10.17.28(B) NMAC (5/15/2012) to not be

 5 mutually exclusive. Accordingly, we conclude that the district court misinterpreted

 6 13.10.17.28(B) NMAC (5/15/2012) and thereby misapplied the definition of “medical

 7 necessity” under the Code. While we recognize that the Superintendent likewise

 8 appeared to rely primarily upon 13.10.17.28(B) NMAC (5/15/2012) as the determinant

 9 of “medical necessity,” and we generally defer to an agency’s interpretation of its own

10 regulation, “we are not bound by the agency’s interpretation and we may substitute our

11 own independent judgment for that of the agency if the agency’s interpretation is

12 unreasonable or unlawful.” Albuquerque Bernalillo Cty. Water Util. Auth. v. N.M.

13 Pub. Regulation Comm’n, 2010-NMSC-013, ¶ 51, 148 N.M. 21, 229 P.3d 494

14 (alteration, internal quotation marks, and citation omitted). To the extent the

15 Superintendent’s use of 13.10.17.28 NMAC (5/15/2012) was mistaken, we are not

16 bound by it or the district court’s ensuing error applying the same provision. See

17 Albuquerque Bernalillo Cty. Water Util. Auth., 2010-NMSC-013, ¶ 51.

18 Barb. 13.10.17.7(L) NMAC (5/15/2012) Provides the Applicable Definition of
19        Medical Necessity Under the Code

                                             20
 1   {27}   13.10.17.7 NMAC (5/15/2012), the applicable definitional section, announces

 2 that “[a]s used in this rule[,]” the meaning of “medical necessity” or “medically

 3 necessary” is established by 13.10.17.7(L) NMAC (5/15/2012). Consistent with the

 4 Superintendent’s authority, we view this generally applicable definition to be that which

 5 should have been applied by the Superintendent to review whether Presbyterian’s

 6 adverse determination regarding coverage of HBOT deprived Jessica of “medically

 7 necessary covered services.” See 13.10.17.29(C) NMAC (5/15/2012); State ex rel.

 8 Helman v. Gallegos, 1994-NMSC-023, ¶ 22, 117 N.M. 346, 871 P.2d 1352 (stating

 9 that when “the meaning of a statute is truly clear—not vague, uncertain, ambiguous,

10 or otherwise doubtful—it is of course the responsibility of the judiciary to apply the

11 statute as written”). The regulation promulgated by the Superintendent reveals the

12 purpose of the external review hearing: “to determine whether, as a result of the health

13 care insurer’s adverse determination, the grievant was deprived of medically necessary

14 covered services.” 13.10.17.29(C) NMAC (5/15/2012). To this end, the Code

15 pointedly defines “medical necessity” or “medically necessary” under 13.10.17.7(L)

16 NMAC (5/15/2012). These rules and regulations govern insurers like Presbyterian. See

17 13.10.17.2(A) NMAC (5/15/2012). Thus, for the purposes of determining whether

18 HBOT was “medically necessary” in Jessica’s circumstances, the Superintendent is

19 constrained by definitional rules it is statutorily empowered to promulgate, one being

                                              21
 1 13.10.17.7(L) NMAC (5/15/2012). It is this provision to which Presbyterian’s contract

 2 and coverage must adhere, even in circumstances where the Code provides

 3 additionally applicable criteria, such as the requisite certification of medical necessity

 4 set forth by 13.10.17.28(B) NMAC (5/15/2012) in the context of “initial external review

 5 of experimental or investigational treatment adverse determinations[.]”

 6 III.     The District Court’s Reversal of the Superintendent Was Erroneous

 7   {28}   While we have held that the district court improperly concluded that HBOT was

 8 a “covered benefit” pursuant to her insurance contract, and improperly applied

 9 13.10.17.28(B) NMAC as the definition of “medical necessity,” we must yet determine

10 whether Presbyterian’s denial of coverage withstands Rodarte’s challenge under

11 13.10.17.7(L).8 See Marckstadt v. Lockheed Martin Corp., 2010-NMSC-001, ¶ 18,

12 147 N.M. 678, 228 P.3d 462 (holding in the context of vehicle insurance that parties’

13 freedom to contract does not excuse them from “the necessity of meeting [applicable]

14 statutory and regulatory requirements”). If the denial of coverage to Jessica was proper

15 under 13.10.17.7(L) NMAC (5/15/2012) as well as the contract, then the

            8
16          We recognize that Presbyterian seeks to prevail based solely upon the language
17   of the contract into which it and Rodarte entered, but we observe no substantive
18   difference, nor does Presbyterian argue one exists, between 13.10.17.7(L) NMAC
19   (5/15/2012) and the insurance contract’s own definition. As we have stated, the health
20   plan contract must conform to applicable provisions of the Code. See
21   13.10.13.8(C)(1) NMAC (requiring “that a covered person shall have the right, at a
22   minimum . . . to available and accessible services when medically necessary”).

                                               22
 1 Superintendent will have reached the proper result and the district court will have erred

 2 in reversing the Superintendent. If, to the contrary, the denial of coverage to Jessica

 3 was improper under 13.10.17.7(L) (5/15/2012), the district court’s reversal

 4 could be correct on grounds not relied on by it. See Meiboom v. Watson, 2000-

 5 NMSC-004, ¶ 20, 128 N.M. 536, 994 P.2d 1154 (stating that an appellate court may

 6 affirm a trial court’s ruling on a ground that was not relied on below if reliance on the

 7 new ground would not be unfair to the appellant). We may not “set aside, reverse[,]

 8 or remand the final decision” of the Superintendent without a determination that it

 9 acted fraudulently, arbitrarily or capriciously, its final decision was not supported by

10 substantial evidence, or was not in accordance with law. Section 39-3-1.1(D). Neither

11 party contends, nor does our review of the record indicate, that the Superintendent

12 acted fraudulently, arbitrarily, or capriciously.

13   {29}   To ascertain whether substantial evidence supported the Superintendent’s final

14 decision upholding Presbyterian’s coverage denial, we look to the record. We note

15 that the Superintendent’s internal review panel first determined that there was a lack of

16 evidence that HBOT improved Jessica’s condition. First, it observed that Jessica’s

17 pre-screening exam was conducted four months prior to the first application of HBOT

18 and was therefore “not an appropriate objective scientific tool for measuring the effect

19 of HBOT.” As well, it concluded that the case studies presented to the panel by Dr.

                                              23
 1 Stoller were not comparable to “high level research studies[,] such as those done in

 2 a prospective, randomized, controlled, double-blinded fashion.” It also pointed to the

 3 absence of evidence establishing a causal linkage between Jessica’s “alleged

 4 improvements” and HBOT treatment, and a study provided by Dr. Stoller that noted

 5 the inability to gauge the efficacy of HBOT when utilized within a year of a traumatic

 6 brain injury. We conclude this to be “relevant evidence that a reasonable mind would

 7 find adequate to support a conclusion[,]” required for a determination of the existence

 8 of substantial evidence. Ponder, 2000-NMSC-033, ¶ 7 (internal quotation marks and

 9 citation omitted). Under 13.10.17.7(L) NMAC (5/15/2012), substantial evidence

10 supported the determination that Rodarte failed to establish the medical necessity of

11 HBOT to treat Jessica’s anoxic brain injury.

12   {30}   Regarding whether the Superintendent acted in conformance with law, we

13 recognize that the erroneous application of 13.10.17.28(B) NMAC (5/15/2012) to the

14 substantive question of medical necessity in this instance can alone serve as the basis

15 to reverse the administrative determination. Here we cannot tell with certainty which

16 provision the Superintendent utilized because he cited a non-existent provision within

17 the Code. We can, however, nonetheless determine that the Superintendent’s ultimate

18 determination that the treatment was not medically necessary should have been

19 affirmed by application of 13.10.17.7(L) NMAC (05/15/2012). See Cordova v. World

                                             24
 1 Fin. Corp. of N.M., 2009-NMSC-021, ¶ 18, 146 N.M. 256, 208 P.3d 901 (stating that

 2 appellate courts may affirm a lower court if it is right for any reason, “so long as the

 3 circumstances do not make it unfair to the appellant to affirm”); see also Martinez v.

 4 N.M. State Eng’r Office, 2000-NMCA-074, ¶ 21, 129 N.M. 413, 9 P.3d 657

 5 (upholding the decision of an administrative law judge on the basis of right for any

 6 reason). Because there is substantial evidence to support the Superintendent’s

 7 determination, we may also conclude that it did not act fraudulently, arbitrarily, or

 8 capriciously. Lastly, because Presbyterian consistently sought enforcement of its

 9 contract by repeated reference to the correct governing standard for medical necessity,

10 as set forth within 13.10.17.7(L) NMAC (5/15/2012), we find no unfairness in our

11 conclusion agreeing, albeit on somewhat different grounds, with the result reached by

12 the Superintendent.

13 CONCLUSION

14   {31}   For the foregoing reasons, we reverse the judgment of the district court and

15 reinstate the final order of the Superintendent upholding Presbyterian’s denial of

16 coverage.

17   {32}   IT IS SO ORDERED.

18                                             _________________________________
19                                            J. MILES HANISEE, Judge

                                              25
26
1 I CONCUR:

2 _________________________________
3 LINDA M. VANZI, Judge

4 VIGIL, Chief Judge (dissenting in part, and specially concurring).

                                       27
 1 VIGIL, Chief Judge (dissenting in part, and specially concurring).

 2   {33}   I dissent in part, and specially concur in the majority opinion for the reasons set

 3 forth below.

 4 DISSENT

 5   {34}   The Code requires all health benefits plans in New Mexico to provide for

 6 medically necessary services. 13.10.17.29(C) NMAC (5/12/2012). However, HBOT

 7 treatments which Rodarte seeks to treat Jessica’s condition are without question

 8 experimental or investigational. As such, they are not “medically necessary” under

 9 Presbyterian’s plan9 and they do not satisfy the Code’s general definition of “medical

10 necessity” set forth in 13.10.17.7(L) NMAC (5/12/2012).10 That is to say, until a

            9
11          Presbyterian’s insurance contract defines “medical necessity” to be:
12   “appropriate or necessary services as determined by a Provider/Practitioner, in
13   consultation with Presbyterian . . . which are provided to a Member for any covered
14   condition requiring, according to generally accepted principles of good medical
15   practice guidelines developed by the federal government, national or professional
16   medical societies, boards, and associations, or any applicable clinical protocols or
17   practice guidelines developed by [Presbyterian] consistent with such federal, national
18   and professional practice guidelines for the diagnosis or direct care and treatment of
19   an illness, injury, or medical condition, and are not services provided only as a
20   convenience.”
         10
21          Unless otherwise indicated , all future references shall be to the 2012 version,
22 and for ease of reference shall be referred to as “Section .7(L).” Section .7(L) defines
23 “medical necessity or medically necessary” as: “health care services determined by a
24 provider, in consultation with the health care insurer, to be appropriate or necessary,

                                                28
1 treatment has been vetted and adopted as the standard of care by the federal

2 government or national or professional medical practice guidelines, the treatment is not

3 “medically necessary” under Presbyterian’s plan and the Code’s general provision.

4    {35}   However, the Code also recognizes that in particular cases an experimental or

5 investigational treatment may be medically necessary for a particular patient such as

6 Jessica. For these cases, the Code expands the classes of treatments that may be

7 required and sets forth the parameters in which an experiment or investigational

8 treatment may be medically necessary. This is 13.10.17.28 NMAC (5/12/2012).11

25   according to any applicable generally accepted principles and practices of good
10   medical care or practice guidelines developed by the federal government, national or
11   professional medical societies, boards and associations, or any applicable clinical
12   protocols or practice guidelines developed by the health care insurer consistent with
13   such federal, national, and professional practice guidelines, for the diagnosis or direct
14   care and treatment of a physical, behavioral, or mental health condition, illness, injury,
15   or disease[.]”
            11
16           Unless otherwise indicated, all future references shall be to the 2012 version,
17   and for ease of reference shall be referred to as “Section .28.” In its entirety Section
18   .28 provides:
19         A.     coverage; the recommended or requested health care service:
20         (1) reasonably appears to be a covered benefit under the grievant’s health
21   benefit plan except for the health care insurer’s determination that the health care
22   service is experimental or investigational for a particular medical condition; and
23         (2) is not explicitly listed as an excluded benefit under the grievant’s health
24   benefit plan; and
25         B.     medical necessity; the grievant’s treating provider has certified that:
26         (1) standard health care services have not been effective in improving the
27   grievant’s condition; or

                                                29
 1 The majority concludes that Section .28 serves only a gatekeeper function by “merely”

 2 setting forth criteria to consider in determining whether to grant administrative review

 3 when a provider has denied coverage for an experimental or investigational treatment.

 4 Majority Op. ¶ 24. The majority then determines that an experimental or investigational

 5 treatment must fulfill an impossibility, which is to satisfy the Code’s general definition

 6 of “medical necessity” in Section .7(L), Majority Op. ¶ 25, and after weighing the

 7 evidence itself, concludes that the HBOT treatments are not “medically necessary”

 8 under Section .7(L). Majority Op. ¶ 27. I dissent from these conclusions.

 9   {36}   Presbyterian denied coverage on the grounds there is no coverage for Jessica’s

10 condition and because the treatment was for “experimental or investigational services

11 [or] treatments.” Rodarte sought administrative review of the denial, and the

16        (2) standard health care services are not medically appropriate for the
17 grievant; or
15        (3) there is no standard health care service covered by the health care insurer
16 that is as beneficial or more beneficial than the health care service:
17        (a) recommended by the grievant’s treating provider that the treating provider
18        certifies in writing is likely to be more beneficial to the grievant, in the treating
19        provider’s opinion, than standard health care services; or
20        (b) requested by the grievant regarding which the grievant’s treating provider,
21        who is a licensed, board certified or board eligible physician qualified to
22        practice in the area of medicine appropriate to treat the grievant’s condition, has
23        certified in writing that scientifically valid studies using accepted protocols
24        demonstrate that the health care service requested by the grievant is likely to be
25        more beneficial to the grievant than available standard health care services.

                                                30
 1 Superintendent granted review under Section .28. The hearing panel appointed by the

 2 Superintendent, took evidence and made a recommended decision. It considered

 3 whether Jessica’s proposed treatment satisfied the criteria of Section .28, and

 4 concluded that it does not. The hearing panel therefore recommended upholding

 5 Presbyterian’s denial of HBOT treatments under Section .28.

 6   {37}   The Superintendent upheld the hearing panel’s recommended decision to deny

 7 coverage. The Superintendent first stated that the issue presented in the administrative

 8 hearing under 13.10.17.29(C) NMAC (5/12/2012) was whether Jessica was deprived

 9 of “medically necessary covered services.” Thus, ruled the Superintendent, the

10 services must be “medically necessary” before Presbyterian’s adverse determination

11 could be reversed. Pertinent to the issue before us, the Superintendent specifically

12 ruled, “Although not expressly stated in the regulations, it is reasonable to infer that,

13 when a treatment is denied because it is deemed to be experimental or investigational,

14 the standard for medical necessity set forth in [Section .28(B)], and relied on by the

15 [p]anel, should be applied to the evidence in the record.” The Superintendent then

16 specifically ruled that the HBOT treatment denied by Presbyterian “does not meet the

17 requirements necessary to establish medical necessity[.]” The Superintendent also

18 added, “pursuant to 13.10.17.B NMAC” which, as the majority opinion points out,

                                              31
 1 does not exist. In my view this error is inconsequential, as the Superintendent and

 2 hearing panel are both clear that they were applying the standard of medical necessity

 3 under Section .28(B) in upholding Presbyterian’s denial. (I infer a typographical error

 4 in typing “13.10.17.B” instead of “13.10.17.28(B)”).

 5   {38}   Rodarte then appealed to the district court, specifically arguing that the HBOT

 6 treatment was “medically necessary” under Section .28(B). As the majority points out,

 7 the district court ultimately considered whether the treatment satisfied the requirement

 8 of “medical necessity” in Section .28. Majority Op. ¶ 9. In its ruling, the district court

 9 ruled that “the proper standard for the ultimate agency review of the medical necessity

10 of an experimental or investigational medical procedure is . . . [Section .28(B)],” and

11 that the specific standard in Section .28(B) applies, rather than the more general

12 definition of “medical necessity” found at Section .7(L). It is from this order that

13 Presbyterian appeals.

14   {39}   Presbyterian, the hearing panel appointed by the Superintendent, the

15 Superintendent, and the district court all concluded that the standard of “medical

16 necessity” under Section .28(B) applies. Disagreeing, the majority holds that it is

17 nothing more than something which must be considered in determining whether to

18 grant administrative review. Majority Op. ¶ 24. Where the majority’s reasoning fails,

                                               32
 1 however, is that it results in granting an administrative hearing which a patient can never

 2 win when coverage is sought for an experimental or investigational treatment, because

 3 such a treatment will never satisfy Section .7(L). As Rodarte points out, “[w]hat would

 4 be the point of permitting appeals that could never, by definition, succeed?” The

 5 answer is that the Code does not provide for a meaningless hearing. Instead, as the

 6 Superintendent ruled, when a treatment is denied because it is deemed to be

 7 experimental or investigational, the standard of medical necessity in Section .28(B)

 8 governs.

 9   {40}   Administrative regulations are to be interpreted under the same basic principles

10 that guide interpretation of statutes. See PC Carter Co. v. Miller, 2011-NMCA-052,

11 ¶ 11, 149 N.M. 660, 253 P.3d 950. As such, “each section or part should be

12 construed in connection with every other part or section, giving effect to each, and

13 each provision is to be reconciled in a manner that is consistent and sensible so as to

14 produce a harmonious whole.” Lion’s Gate Water v. D’Antonio, 2009-NMSC-057,

15 ¶ 23, 147, N.M. 523, 226 P.3d 622 (internal quotation marks and citation omitted).

16 Moreover, “The general/specific rule provides that when two statutes deal with the

17 same subject matter, the statute dealing with a specific subject will be considered an

18 exception to, and given effect over, the more general statute.” Lu v. Educ. Trust Bd.

                                               33
 1 of N.M., 2013-NMCA-010, ¶ 13, 293 P.3d 186 (alteration, internal quotation marks,

 2 and citation omitted). Finally, a regulation should be interpreted with common sense,

 3 and an interpretation that leads to absurdity or contradiction should be avoided. See

 4 Baker v. Hedstrom, 2013-NMSC-043, ¶ 36, 309 P.3d 1047. Application of these

 5 settled principles requires that, in the case of an experimental or investigational

 6 treatment, the definition of “medical necessity” in Section .28 governs instead of the

 7 general definition of “medical necessity” in Section .7(L). Since the majority disagrees,

 8 I dissent. I therefore agree with the hearing panel, the Superintendent, and the district

 9 court that Section .28 governs administrative review when treatment has been denied

10 on the basis that it is experimental or investigational.

11 SPECIAL CONCURRENCE

12   {41}   The foregoing dissent notwithstanding, I agree with the majority that the order

13 of the district court must be reversed. However, I arrive at this conclusion under

14 Section .28.

15   {42}   Under subsection (A) of Section.28, it must be considered: (1) whether HBOT

16 reasonably appears to be a covered benefit under Presbyterian’s plan, except for

17 Presbyterian’s determination that HBOT is experimental or investigational; and (2)

18 HBOT is not explicitly listed as an exclusion under Presbyterian’s plan. Part I of the

                                              34
 1 majority opinion in ¶¶ 12-16 demonstrates that Presbyterian’s insurance contract does

 2 not provide coverage for Jessica’s medical condition. I fully concur in this portion of

 3 the majority opinion. Moreover, this part of the majority opinion also demonstrates that

 4 the HBOT treatments are not only not specifically covered under Presbyterian’s health

 5 plan, they are specifically excluded. I therefore conclude that Rodarte failed to prove

 6 that subsection (A) of Section .28 was satisfied.

 7   {43}   I next consider whether subsection (B) of Section .28 was satisfied. The issue

 8 presented to the hearing panel was whether the HBOT treatments were “medically

 9 necessary” under Section .28(B)(3)(b).

10   {44}   In seeking to prove such “medical necessity” Jessica’s treating physician, Dr.

11 Ken Stoller certified that there is no standard health care service covered by

12 Presbyterian that is as beneficial or more beneficial than the proposed HBOT

13 treatments. The hearing panel noted, however, that “the issue is a lack of high level

14 research studies such as those done in a prospective, randomized, controlled, double-

15 blinded fashion. Dr. Stoller presented several case studies in his materials, but case

16 studies are not a substitute [for] the types of studies just described in the medical

17 field.” After noting Jessica’s treatments by Dr. Stoller, and Jessica’s response to those

18 treatments, the hearing panel concluded, “Due to the lack of evidence that HBOT

                                              35
 1 caused Ms. Rodarte’s alleged improvements and the fact that she was provided

 2 HBOT treatment within the first year following her diagnosis of anoxic encephalopathy

 3 when spontaneous improvement can occur, it is not clear that HBOT caused Ms.

 4 Rodarte’s improvements.” Based on its review of the evidence, the hearing panel

 5 concluded that the evidence failed to demonstrate that the HBOT treatments were

 6 medically necessary under Section .28(B). The Superintendent in turn adopted,

 7 approved, and accepted the hearing panel’s recommendation.

 8   {45}   I conclude that substantial evidence supports the Superintendent’s conclusion

 9 that the HBOT treatments were not medically necessary under Section .28(B). I

10 therefore agree with the majority that the district court erred. However, I disagree with

11 the majority that independently examining the evidence to determine whether it satisfies

12 section .7(L) is necessary or appropriate. See Majority Op. ¶¶ 26-28.

13   {46}   I therefore specially concur in the result reached.

14
15
16                                           MICHAEL E. VIGIL, Chief Judge

                                               36